PYXS ▲ +9.0% - Pyxis Oncology, Inc. $PYXS - Pyxis Oncology to Host Webcast to Present Updated Data from Phase 1 Monotherapy Study of Micvotabart Pelidotin (MICVO) in Second-Line and Beyond Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (2L+ R/M HNSCC) Pyxis Oncology shares rose 9.0% following the company's announcement that it will host a webcast to present updated Phase 1 data for its experimental therapy micvotabart pelidotin in patients with recurrent or metastatic head and neck cancer. The presentation of clinical trial results typically attracts investor interest, particularly when updates are being formally highlighted through a scheduled event. 08-SEP-2026 04:01 PM ET